China's Rise in Biotech: Can AI Driven Breakthroughs Deliver? Alex Zhavoronkov, co CEO of Insilico Medicine, has made a bold bet on China as the next hub for biotech innovation.
His company's recent announcement that its AI discovered drug rentosertib will start Phase 3 trials in China is just one example of the country's growing influence in the field.
Insilico's use of artificial intelligence to identify disease targets and develop molecules has been hailed as a game changer, with some suggesting it could slow or reverse aging.